EVALUACIÓN DEL USO Y EFICACIA DEL CANNABIDIOL PARA EL TRATAMIENTO DE TRASTORNOS DE ANSIEDAD Y DEPRESIÓN
DOI:
https://doi.org/10.47820/recima21.v6i2.6180Palabras clave:
Cannabidiol. Depresión. Ansiedad.Resumen
La presente revisión destaca el uso del cannabidiol (CBD) como alternativa terapéutica para trastornos de ansiedad y depresión, resaltando su interacción con el sistema endocannabinoide y los receptores 5HT1A, responsables de la regulación del estado de ánimo y el estrés. Materiales y Métodos: se trata de una revisión integrativa de la literatura de artículos publicados entre 2015 y 2024, utilizando la estrategia PICO para definir la eficacia del CBD en comparación con placebo y tratamientos convencionales. Resultados y Discusión: Se incluyeron 11 estudios que indicaron resultados variados: mientras algunos demostraron reducciones significativas en los síntomas de ansiedad y depresión, otros mostraron evidencias inconclusas o beneficios limitados. Conclusión: Aunque el CBD ha demostrado ser seguro y potencialmente eficaz, especialmente en formulaciones específicas y para poblaciones seleccionadas, se destaca la necesidad de estudios más sólidos. En conclusión, el CBD se presenta como un enfoque terapéutico emergente, pero aún carece de validación científica integral para su aplicación clínica rutinaria.
Descargas
Referencias
BERGER, Maximus et al. “Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.” The Journal of clinical psychiatry, v. 83, 3 aug. 2022. DOI: https://doi.org/10.4088/JCP.21m14130
BLACK, Nicola et al. “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.” The lancet. Psychiatry, v. 6, n. 12, p. 995-1010, 2019. DOI: https://doi.org/10.1016/S2215-0366(19)30401-8
BLEBEA, Nicoleta Mirela et al. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. International Journal of Molecular Sciences, v. 25, n. 8, p. 4204, 2024. DOI: https://doi.org/10.3390/ijms25084204
BONACCORSO, Stefania et al. “Cannabidiol (CBD) use in psychiatric disorders: A systematic review.” Neurotoxicology, v. 74, p. 282-298, 2019. DOI: https://doi.org/10.1016/j.neuro.2019.08.002
BRANDÃO RODRIGUES, Bráulio; ROCHA ALVARENGA, Lara Cristina e AGUIAR, Cárita. Uso terapêutico do canabidiol nos transtornos de ansiedade e insônia. Brazilian Journal of Development, Curitiba, v. 8, n. 12, p. 79140-79152, dec. 2022. DOI: https://doi.org/10.34117/bjdv8n12-152
DAMMANN, Inga et al. “Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review.” Pharmacopsychiatry, vo. 57, n. 3, p. 115-132, 2024. DOI: https://doi.org/10.1055/a-2228-6118
DE SOUSA, Luís Manuel Mota et al. A metodologia de revisão integrativa da literatura em enfermagem. Revista investigação em enfermagem, v. 21, n. 2, p. 17-26, 2017.
DEGENHARDT, Louisa; HALL,Wayne e LYNSKEY, Michael. Exploring the association between cannabis use and depression. Addiction, v. 98, n. 11, p. 1493-504, nov. 2003. DOI: https://doi.org/10.1046/j.1360-0443.2003.00437.x
DEVANE, William Anthony et al. “Determination and characterization of a cannabinoid receptor in rat brain.” Molecular pharmacology, v. 34, n. 5, p. 605-13, 1988. DOI: https://doi.org/10.1016/S0026-895X(25)09876-1
ERCOLE, Flávia Falci; MELO, Laís Samara de; ALCOFORADO, Carla Lúcia Goulart Constant. Revisão integrativa versus revisão sistemática. Reme: Revista Mineira de Enfermagem, v. 18, n. 1, p. 09-11, 2014. DOI: https://doi.org/10.5935/1415-2762.20140001
GARCÍA-GUTIÉRREZ, María S. et al. “Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.” Biomolecules, v. 10, n. 11, p. 1575, 19 nov. 2020. DOI: https://doi.org/10.3390/biom10111575
GUNDUGURTI, Prasad Rao et al. “Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.” Asian journal of psychiatry, v. 97, 2024. DOI: https://doi.org/10.1016/j.ajp.2024.104073
HILL, Matthew N.; GORZALKA, Boris B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behavioural pharmacology, v. 16, n. 5-6, p. 333–352, 2005. DOI: https://doi.org/10.1097/00008877-200509000-00006
JAVAID, Syed Fahad et al. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Current Psychiatry, v. 30, n. 1, p. 44, 2023. DOI: https://doi.org/10.1186/s43045-023-00315-3
KWEE, Caroline M. B. et al. “Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial.” European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, v. 59, p. 58-67, 2022. DOI: https://doi.org/10.1016/j.euroneuro.2022.04.003
LINGE, Raquel et al. “Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.” Neuropharmacology, v. 103, p. 16-26, 2016. DOI: https://doi.org/10.1016/j.neuropharm.2015.12.017
MASATAKA, Nobuo. “Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders.” Frontiers in psychology, v. 10, n. 8, nov. 2019. DOI: https://doi.org/10.3389/fpsyg.2019.02466
MCINTYRE, Roger S. et al. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry, v. 22, n. 3, p. 394-412, 2023. DOI: https://doi.org/10.1002/wps.21120
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008. DOI: https://doi.org/10.1590/S0104-07072008000400018
ORTIZ, Yuma T.; MCMAHON, Lance R.; WILKERSON, Jenny L. Medicinal cannabis and central nervous system disorders. Frontiers in pharmacology, v. 13, p. 881810, 2022. DOI: https://doi.org/10.3389/fphar.2022.881810
PINTORI, Nicholas et al. THC and CBD: villain versus hero? Insights into adolescent exposure. International Journal of Molecular Sciences, v. 24, n. 6, p. 5251, 2023. DOI: https://doi.org/10.3390/ijms24065251
PRZEMYSŁAW, Adamczyk et al. “Activation of endocannabinoid transmission induces antidepressant-like effects in rats.” Journal of physiology and pharmacology: an official journal of the Polish Physiological Society, v. 59, n. 2, 217-28, 2008.
ROBSON, Philip. “Therapeutic aspects of cannabis and cannabinoids.” The British journal of psychiatry: the journal of mental science, v. 178, p. 107-15. 2001. DOI: https://doi.org/10.1192/bjp.178.2.107
SOUZA, José Diogo S. et al. “Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic.” Frontiers in pharmacology, v. 13, 3 oct. 2022. DOI: https://doi.org/10.3389/fphar.2022.856846
WIECKIEWICZ, Gniewko et al. Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists. Frontiers in Psychiatry, v. 13, 2022. DOI: https://doi.org/10.3389/fpsyt.2022.837946
Descargas
Publicado
Número
Sección
Categorías
Licencia
Derechos de autor 2025 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
